Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Xenon ( (XENE) ) just unveiled an announcement.
On June 4, 2025, Xenon Pharmaceuticals Inc. conducted its 2025 Annual Meeting of Shareholders, where approximately 94.10% of the total common shares entitled to vote were present. During the meeting, shareholders voted on four proposals: the election of directors, advisory vote on executive compensation, appointment of PricewaterhouseCoopers LLP as the independent auditor, and the remuneration of the auditor. All proposals were approved, reflecting strong shareholder support and potentially reinforcing the company’s governance and operational strategies.
The most recent analyst rating on (XENE) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
Xenon’s primary strengths lie in its strong financial position and positive clinical development progress, as highlighted in the earnings call. However, the absence of revenue and profitability, along with technical and valuation concerns, weigh heavily on the overall stock score.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapeutics to address neurological disorders.
Average Trading Volume: 974,984
Technical Sentiment Signal: Sell
Current Market Cap: $2.36B
For an in-depth examination of XENE stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue